Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

Abstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxte...

Full description

Bibliographic Details
Main Authors: Laura Alder, Dario Trapani, Claire Bradbury, Amanda E. D. Van Swearingen, Sara M. Tolaney, Mustafa Khasraw, Carey K. Anders, Christopher D. Lascola, Liangge Hsu, Nancy U. Lin, Sarah Sammons
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00519-0

Internet

https://doi.org/10.1038/s41523-023-00519-0

Similar Items